Blood

Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors.

Blood

Catherine C. Smith, Aaron D. Viny, Evan S. Massi, Cyriac Kandoth, Nicholas D. Socci, Henry Hsu, Brian West, Gideon Bollag, Barry S. Taylor, Ross L. Levine, Neil P. Shah

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study.

Blood

Catherine C. Smith, Mark J. Levis, Mark R Litzow, Alexander E. Perl, Jessica K. Altman, Stanley C. Gill, Takeshi Kadokura, Geoffrey J. Yuen, Ogert Fisniku, Charles Liu, Itsuro Nagase, Briana Sargent, Noreen Welter, Erkut Bahceci

Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia.

Blood

Huimin Geng, Zhengshan Chen, Shawn Anderson, Eleanor Fraser, Ming Lu, Chen Lingjing, Colin Collins, Muschen Markus, James L. Rubenstein

Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia.

Blood

Zhengshan Chen, Huimin Geng, Clifford A. Lowell, Arthur Weiss, Stephen P. Hunger, Ari Melnick, Markus Muschen

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL.

Blood

Sanghoon Lee, Changhong Yin, Janet Ayello, Erin Morris, Timmy O'Connell, Lauren Harrison, Carmella van de Ven, Matthew J. Barth, Rodney R. Miles, Paul J. Galardy, Stanton Goldman, Megan S Lim, Michelle L. Hermiston, Linda McAllister-Lucas, Lisa Giulino-Roth, Sherrie L. Perkins, Mitchell S. Cairo

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL.

Blood

Sanghoon Lee, Changhong Yin, Janet Ayello, Erin Morris, Lauren Harrison, Carmella van de Ven, Matthew J. Barth, Rodney R. Miles, Paul J. Galardy, Stanton Goldman, Megan S Lim, Michelle L. Hermiston, Linda McAllister-Lucas, Lisa Giulino-Roth, Sherrie L. Perkins, Mitchell S. Cairo

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma.

Blood

Megan Murnane, Eugen Dhimolea, Ruojing Li, Megan A. Bariteau, Diamond D. Wheeler, Rosemary J. Akhurst, Aaron C. Logan, Pamela Munster, Arun Wiita, Thomas G. Martin, Jeffrey L. Wolf, Jun O. Liu, Constantine S. Mitsiades, Blake T. Aftab

A Tailor-Made Protein Synthesis Program Drives Erythroid Development and Disease.

Blood

Craig M Forester, Zhen Shi, Maria Barna, Davide Ruggero

A Genome-Wide Association Study of Myeloma Survival in Utah Uncovers Germline Variants That May Influence Survival of Multiple Myeloma Patients.

Blood

Karen Curtin, Yi Zhao, Donglei Hu, Guido J Tricot, Elad Ziv, Djordje Atanackovic, Nicola J Camp

Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary Syndrome.

Blood

Weiyun Ai, Chen-Yen Yang, Razan Faraj, Taha Rakhshandhroo, Shervin Afghani, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick

Pages